Biofrontera Sells Xepi License to Pelthos for Up to $10M

Friday, Nov 7, 2025 8:09 am ET1min read

• Biofrontera sells Xepi license to Pelthos for up to $10M • Proceeds bolster cash position, expected to fund to profitability • Supports growth of PDT platform and expansion of Ameluz into new indications • Transaction bolsters Biofrontera's financial position, enabling further development • Milestone payments of up to $6M contingent on sales performance • Expected to fund Biofrontera's commercial and R&D activities.

Comments



Add a public comment...
No comments

No comments yet